Lisata Therapeutics vs Soligenix
LSTA and SNGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LSTA and SNGX compare
Lisata Therapeutics is the larger company, worth 1.5 times as much as Soligenix ($9.4M against $6.1M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LSTA | SNGX |
|---|---|---|
| Size and price | ||
| Market cap | $9.4M | $6.1M |
| Share price | $1.04 | $0.281 |
| Change, 1 year | −50.9% | −79.5% |
| Change, 5 years | −92.9% | −99.9% |
| Beta (5Y) | −1.59 | 2.38 |
| Employees | 21 | 14 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 93.7× | – |
| P/B | 1.1× | 0.9× (better) |
| FCF yield | −131% | – |
| Growth | ||
| Revenue growth (TTM) | −90.7% | – |
| Profitability | ||
| Operating margin | −16427% | – |
| Net margin | −14621% | – |
| FCF margin | −12323% | – |
| Return on equity | −99.9% (better) | −242% |
| Return on invested capital | −1645% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 3.69 (better) | 2.77 |
| Altman Z-score | −74.81 | −35.09 (better) |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Buyback yield | −6.3% | – |
| Shareholder yield | −6.3% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 12.1% | 4.3% |
| Held by insiders | 11.6% | 0.69% |
| Short interest, % of float | 0.43% | 0.31% |
Go deeper
- LSTA stock overview
- LSTA income statement
- LSTA valuation and score
- SNGX stock overview
- SNGX income statement
- SNGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.